STRUCTURE PREDICTION AND IN SILICO DESIGNING OF DRUGS AGAINST KALLIKREIN PROTEIN 12
Objective: Human Kallikrein protein 12 (hK12) might serve as a novel diagnostic and prognostic biomarker, as well as a potential therapeutic target, in gastric cancer.
Methods: In this work, a theoretical model of hK12 receptor protein was generated using the concepts of homology modeling and loop modeling. The resulting model was validated with Ramachandran plot analysis. The ligands generated with the help of Drug bank were docked against hK12 receptor protein using AutoDock Vina in PyRx 0.8. The structure of ligand DB04786 (Suramin), with least binding energy, was varied by using ACD/ChemSketch 8.0 and the docking was done for the resulting 16 new ligands.
Results: The results indicated that the ligand10 bears the minimum binding energy (-12.3 Kcal/mol) with the target protein and thus the prospects of binding are high. The results also clearly demonstrated that the in silico molecular docking studies of selected ligands, i.e., suramin, ligands 5, 6, 10 and 16 with hK12 protein exhibited favourable binding interactions and warranted.
Conclusion: Further studies needed for the development of potent inhibitors for the overexpression of hK12 protein making the management of gastric cancer more efficient.
2. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi57-vi63.
3. Kanat O, Neil BO, Shahda S. Targeted therapy for advanced gastric cancer: a review of current status and future prospects. World J Gastrointest Oncol 2015;7:401-10.
4. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002;48:1198-205.
5. BorgoÃ±o CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-90.
6. Kim H, Scorilas A, Katsaros D, Yousef GM, Massobrio M, Fracchioli S, et al. Human kallikrien gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 2001;84:643-50.
7. Mavridis K, Scorilas A. Prognostic value and biological role of the kallilrein-related peptidases in human malignancies. Future Oncol 2010;6:269-85.
8. Wu Y, Lu M, Zhou Q. Kallikrein expression as a prognostic factor in ovarian cancer: a systematic review and meta-analysis. J Buon 2015;20:855-61.
9. Yang F, Li JY, Yin QN, Yang K, Dong SN, Bai LJ, et al. Human kallikrein 5 as a novel prognostic biomarker for triple-negative breast cancer: tissue expression analysis and relationship with disease course. Genet Mol Res 2015;14:9655-66.
10. Nagahara H, Mimori K, Utsunomiva T, Barnard GF, Ohira M, Hirakawa W, et al. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res 2005;11:6800-6.
11. Feng B, Xu WB, Zheng MH, Ma JJ, Cai Q, Zhang Y, et al. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol 2006;21:1596-603.
12. Wen YG, Wang Q, Zhou CZ, Yan DW, Qiu GQ, Yang C, et al. Identification and validation of kallikrein-related peptidase 11 as a novel prognostic marker of gastric cancer based on immunohistochemistry. J Surg Oncol 2011;104:516-24.
13. Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin Biochem 2010;43:1205-11.
14. Memari N, Diamandis EP, Earle T, Campbell A, Van Dekken H, Van der Kwast TH. Human kallikrein-related peptidase 12: antibody generation and immunohistochemical localization in prostatic tissues. Prostrate 2007;67:1465-74.
15. Yousef GM, Magklara A, Diamandis EP. KLK 12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 2000;69:331-41.
16. Zhao EH, Shen ZY, Liu H, Jin X, Cao H. Clinical significance of human kallikrein 12 gene expression in gastric cancer. World J Gastroenterol 2012;18:6597-604.
17. Yang SSO, Lu JY, Kong XQ, Liang ZJ, Luo C, Jiang H. Computational drug discovery. Acta Pharm Sinic 2012;33:1131-40.
18. Devgan M. Homology modelling and molecular docking studies of DNA replication licensing factor minichromosome maintenance protein 5 (MCM5). Asian J Pharm Technol 2015;5:17-22.
19. Devgan M. Structure prediction and in silico designing of drugs for the inhibition of Eph A10 tyrosine kinase receptor protein. Acta Biol Sci 2016;3:86-94.
20. Devgan M. Structure prediction and in silico designing of drugs against homeobox C8 protein. J Chem Pharm Res 2016;8:891-9.
21. Devgan M, Karar PK, Agarwal G, Mohan A, Gangwar P. In silico designing of drugs for the inhibition of AMF-HER2 complex in trastuzumab-resistant breast cancer. Indian J Biotechnol 2016;15:292-8.
22. Wikipedia. The free encyclopedia [Internet]. San Franscisco (CA): Wikipedia Foundation, Inc (US); c2001-16. Available from: https://en.wikipedia.org/wiki/FASTA_format. [Last accessed on 19 Jan 2016]
23. National Center for Biotechnology Information [Internet]. Bethesda (MD): National Library of Medicine (US); Kallikrein 12 [Homo sapiens]. Available from: http:// www.ncbi.nlm.nih.gov/rotein/10799397?report=fasta. [Last accessed on 22 Oct 2015]
24. Wikipedia. The free encyclopaedia [Internet]. San Franscisco (CA): Wikipedia Foundation, Inc (US); 2001-2016. BLAST. Available from: https://en.wikipedia.org/wiki/BLAST. [Last accessed on 19 Jan 2016].
25. National Center for Biotechnology Information [Internet]. Bethesda (MD): National Library of Medicine (US); BLASTP. Available from: http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastandPAGE_TYPE=BlastSearch. [Last accessed on 23 Oct 2015]
26. Kelly L. 3D-PSSM. South Kensington Campus (London): Imperial College of Science, Technology and Medicine (UK); c1999. Available from: http://sbg.bio.ic.ac.uk/~3dpssm/index2.html. [Last accessed on 23 Oct 2015]
27. Kelly LA, Sternberg MJ. Protein structure prediction on the web: a case study using the Phyre server. Nat Protoc 2009;4:363-71.
28. Kelly L, Sternberg M. Phyre2 [Internet]. South Kensington Campus (London): Structural Bioinformatics Group, Imperial College (UK). Available from: http://www.sbg.bio.ic.ac.uk/ ~phyre2/html/page.cgi?id=index. [Last accessed on 23 Oct 2015]
29. Research Collaboratory for Structural Bioinformatics. RCSB Protein Data Bank [Internet]. New Jersey, California: Rutgers, UCSanDiego (US). Available from: http://www.rcsb.org/pdb/home.do. [Last accessed on 24 Oct 2015]
30. Kuntal BK, Aparoy P, Reddanna P. EasyModeller: a graphical interface to modeller. BMC Res Notes 2010;3:226.
31. Kuntal BK. EasyModeller (Version 2.0) [Internet]. Hyderabad: Kuntal Kumar Bhusan, University of Hyderabad (India). Available from: http://www.sites.google.com/site/bioinformatikz. [Last accessed on 08 Apr 2015]
32. Duex N, Peitsch M, Schwede T, Diemand A. DeepView/Swiss-PdbViewer [Internet]. Bazel: Structural Bioinformatics Groups, Swiss Institute of Bioinformatics, Biozentrum University of Bazel (Switzerland); c1995-2001. Available from: http://Spdbv.vital-it.ch/ [Last accessed on 06 Apr 2015]
33. European Bioinformatics Institute (EMBL-EBI). PDBsum [Internet]. Hinxton, Cambridgeshire: Wellcome Trust Genome Campus (UK); cEMBL-EBI; 2016. Available from: https://www.ebi.ac.uk/ thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=index.html. [Lase accessed on 24 Oct 2015]
34. Laskowski RA. PDBsum new things. Nucleic Acids Res 2009;37:D355-9.
35. Fiser A, Do RK, Sali A. Modeling of loops in protein structures. Protein Sci 2000;9:1753-73.
36. Fiser A, Sali A. ModLoop: automated modelling of loops in protein structures. Bioinformatics 2003;19:2500-1.
37. Fiser A. ModLoop [Internet]. San Francisco (CA): University of California (USA); c2000. Available from: http://modbase. compbio.ucsf.edu/modloop/. [Last accessed on 25 Oct 2015]
38. Bakker PD, Lovell S. RAMPAGE [Internet]. Cambridge (UK): Department of Biochemistry, University of Cambridge. Available from: http://mordred.bioc.cam.ac.uk/~rapper/rampage.php. [Last accessed on 25 Oct 2015]
39. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34:D668-72.
40. Wishart DS. DrugBank [Internet]. Canada: Canadian Institutes of Health Research, Alberta Innovates-Health Solutions, The Metabolomics Innovation Centre. Available from: http:// www.drugbank.ca. [Last accessed on 28 Oct 2015]
41. Vyas V, Jain A, Jain A, Gupta A. Virtual screening: a fast tool for drug design. Sci Pharm 2008;76:333-60.
42. Forli S. Charting a path to success in virtual screening. Molecules 2015;20:18732-58.
43. PerkinElmer. ChemBio3D. Waltham, Massachusetts: PerkinElmer Inc. (USA); c1998-2016. Available from: http:// www.cambridgesoft.com/Ensemble for chemistry/ chemBio3D/. [Last accessed on 02 Nov 2015]
44. SchrÃ¶dinger. PyMol. New York: SchrÃ¶dinger (USA); c2005-16. Available from: http://www.pymol.org. [Last accessed on 02 Nov 2015].
45. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol 2015;1263:243-50.
46. Dallakyan S. Python prescription, a virtual screening tool. New York: Source Forge, Slashdot Media, DHI Group Inc. (USA); C2009-16. Available from: http://pyrx.sourceforge.net/. [Last accessed on 11 Dec 2015].